Rescue Treatment Pattern, Drug Resistance Recurrence, and Direct Medical Costs Associated With Chinese Patients With Chronic Hepatitis B and Drug Resistance to Nucleot(s)Ide Analogue Therapy

Bristol-Myers Squibb383 enrolled

Overview

The purpose of this study is to describe current rescue treatment pattern for nucleot(s)ide analogue (NA) resistance and assess the real-world treatment outcomes and health resources utilization of rescue treatments for drug resistance in a clinical cohort of Chinese patients with chronic hepatitis B (CHB).

Study Type

OBSERVATIONAL

Enrollment

383

Conditions

Hepatitis B

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * CHB patient with drug resistance confirmed by hepatitis B virus (HBV) gene mutation and virological breakthrough * Patient receiving rescue treatments for drug resistance to previous NA therapy for CHB * Patient who was regularly followed at least every 6 months for drug resistance at the tertiary liver clinic of SXH Exclusion Criteria: * Patient with a diagnosis of hepatocellular carcinoma, decompensated cirrhosis, and/or liver transplantation prior to the development of drug resistance to NA therapy for CHB * Patient with co-infection with hepatitis C virus, hepatitis D virus, and/or human immunodeficiency virus * Patient with life expectancy less than 6 months after the date of the first laboratory test indicating drug resistance Other protocol defined inclusion/exclusion criteria could apply

Locations (1)

Local Institution

Changsha, Hunan, China

Outcomes

Primary Outcomes

Direct medical costs associated with CHB patients who were regularly followed for drug resistance to NA therapy at the tertiary liver clinic of the Second Xiangya Hospital (SXH) in Changsha, Hunan, China